Gallup Cannabis Polling: Tracking American Attitudes on Marijuana Since 1969

Executive Summary

Gallup's cannabis polling has tracked American attitudes toward marijuana legalization since 1969, documenting one of the most dramatic shifts in public opinion in modern U.S. history. From just 12% support in its inaugural survey to consistent majorities exceeding 68% by 2023, Gallup's longitudinal data provides the gold standard for understanding evolving cannabis acceptance across demographics, regions, and political affiliations. The polling organization's September 2026 findings revealed that 25% of middle-aged Americans (ages 35-54) now report current marijuana use, marking a significant milestone in normalization among a demographic traditionally characterized by lower consumption rates. This data carries profound implications for state legislators weighing legalization measures, investors evaluating total addressable market size, and federal policymakers confronting the widening gap between Schedule I classification and mainstream acceptance. Gallup's methodology—consistent question wording, probability sampling, and multi-decade continuity—makes its cannabis surveys uniquely valuable for tracking cultural transformation and predicting policy trajectories.

Why Gallup Cannabis Polling Matters

Gallup's cannabis data directly influences legislative outcomes, corporate strategy, and federal rescheduling debates by providing statistically rigorous evidence of public sentiment. State legislators in holdout jurisdictions cite Gallup's state-level breakdowns when drafting ballot initiatives. In 2024, Kentucky lawmakers referenced Gallup data showing 58% in-state support when advancing medical cannabis legislation. Investment analysts use Gallup's demographic consumption data to model total addressable market—the 2026 finding that one in four middle-aged Americans uses cannabis expanded TAM estimates by $8-12 billion across MSO equity research reports.

For patients and advocates, Gallup polling provides empirical ammunition against stigma. When 70% of Americans support legalization according to Gallup's 2023 survey, prohibitionist arguments lose democratic legitimacy. The Drug Enforcement Administration cited shifting public opinion—documented primarily through Gallup—in its 2024 notice of proposed rulemaking to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (21 U.S.C. § 812).

The financial stakes are substantial. Legal cannabis sales reached $33 billion in 2023, but Gallup data suggesting 50+ million current users implies significant illicit market persistence. Operators use Gallup's age cohort breakdowns to target marketing—the 2026 revelation that middle-aged consumption now matches younger demographics prompted dispensaries to redesign product lines and retail environments for Gen X consumers with higher disposable income.

Background and History: Six Decades of Gallup Cannabis Surveys

Gallup conducted its first cannabis legalization poll in October 1969, when just 12% of Americans supported legal marijuana and President Nixon was months away from signing the Controlled Substances Act. That inaugural survey established the question wording Gallup would use with minor variations for over 50 years: "Do you think the use of marijuana should be made legal, or not?" The consistency enables direct year-over-year comparison unmatched by other polling organizations.

The Prohibition Consensus Era (1969-1995)

Throughout the 1970s and 1980s, support for legalization remained below 30%. Gallup's 1977 survey recorded 28% support—the high-water mark for that era—before Ronald Reagan's drug war rhetoric drove numbers back down. By 1986, amid "Just Say No" campaigns and mandatory minimum sentencing, support fell to 23%. The polling reflected cultural attitudes shaped by the Comprehensive Crime Control Act of 1984 and the Anti-Drug Abuse Act of 1986, which created the 100-to-1 crack-versus-powder cocaine sentencing disparity and expanded asset forfeiture.

Gallup's 1995 survey showed support stuck at 25%, even as California advocates gathered signatures for Proposition 215, the nation's first medical cannabis initiative. The polling suggested medical legalization would face uphill battles—yet Prop 215 passed in 1996 with 56% support, demonstrating that medical-specific framing polled better than general legalization questions.

The Medical Cannabis Shift (1996-2012)

After California's breakthrough, Gallup began tracking medical versus recreational support separately. Its 1999 survey found 73% supported legal medical cannabis—a 48-point gap over recreational support. This divergence shaped state-level strategy for the next decade. Between 1996 and 2012, 18 states enacted medical cannabis programs, while recreational legalization remained politically toxic.

Gallup's 2000 survey recorded 31% support for general legalization, rising to 36% by 2005. The slow creep reflected generational replacement—Silent Generation opponents aging out, Boomers and Gen X entering peak political influence. Gallup's demographic crosstabs showed support among 18-29 year-olds reached 46% by 2003, while those 65+ remained below 15%.

The Majority Tipping Point (2013-2023)

Gallup's October 2013 survey marked a historic inflection: for the first time, a majority of Americans (58%) supported marijuana legalization. The timing coincided with Colorado and Washington implementing voter-approved recreational sales in January 2014. The polling gave political cover to legislators in other states—if nearly 60% of Americans supported legalization, swing-district representatives could vote yes without career risk.

Support climbed steadily: 60% in 2016, 64% in 2017, 66% in 2018. Gallup's 2019 survey recorded 66% support with notable partisan convergence—51% of Republicans now supported legalization, up from 34% just four years earlier. This Republican shift proved crucial for state-level progress in red states. Oklahoma voters approved medical cannabis in 2018; South Dakota (though later overturned by courts) and Montana legalized recreational use in 2020.

The COVID-19 pandemic correlated with another jump. Gallup's November 2020 survey showed 68% support—a new record. Essential business designations for dispensaries during lockdowns normalized cannabis retail. By 2023, Gallup recorded 70% support, with supermajorities across nearly every demographic except Republicans 65+.

The Consumption Surveys (2013-Present)

In 2013, Gallup expanded beyond legalization attitudes to measure self-reported consumption. That first survey found 7% of Americans reported current marijuana use (defined as use within the past week). The figure rose incrementally: 11% in 2016, 12% in 2017, 14% in 2019, 16% in 2021. Gallup's July 2023 survey recorded 17% of American adults as current users—approximately 45 million people.

The September 2026 survey revealed the most striking consumption finding to date: 25% of Americans aged 35-54 reported current marijuana use, surpassing the 22% rate among 18-34 year-olds. This inversion challenged assumptions that cannabis was primarily a youth phenomenon. Middle-aged consumption rates had doubled since 2019, when Gallup recorded just 12% among 35-54 year-olds.

Key Players in Gallup Cannabis Polling

Gallup Organization

Founded in 1935 by George Gallup, the Gallup Organization pioneered scientific public opinion polling and maintains the longest-running cannabis survey series in existence. Gallup uses random-digit-dial telephone methodology with cellphone supplementation, achieving representative national samples of approximately 1,000 adults per survey (margin of error ±4 percentage points at 95% confidence). The organization's reputation for methodological rigor—it does not accept advocacy group funding for cannabis surveys—gives its findings credibility with policymakers across the political spectrum.

Gallup's cannabis polling is conducted through its Gallup Poll Social Series, which rotates topics monthly. Cannabis questions typically appear in the July or October waves. The organization publishes topline results publicly while offering deeper demographic crosstabs to institutional subscribers. Senior Scientist Dr. Frank Newport oversaw cannabis polling methodology from 1991 through 2018; current Gallup analysts continue his protocols to maintain longitudinal consistency.

National Organization for the Reform of Marijuana Laws (NORML)

Founded in 1970, NORML has cited Gallup polling in advocacy campaigns since the 1970s. The organization maintains a public database of Gallup cannabis surveys dating to 1969, using the data to demonstrate the gap between public opinion and federal prohibition. NORML's legal team referenced Gallup's 70% support figure in amicus briefs supporting state legalization measures challenged in federal court. Executive Director Erik Altieri said in 2023 that Gallup data "provides the empirical foundation for our argument that cannabis prohibition lacks democratic consent."

Marijuana Policy Project (MPP)

The Marijuana Policy Project, founded in 1995, uses Gallup data to identify winnable state campaigns. MPP's analytics team cross-references Gallup's national demographic breakdowns with state-level census data to model in-state support before committing resources to ballot initiatives. According to MPP's 2022 strategic plan, states where Gallup crosstabs show 60%+ support among likely voters receive priority funding. This Gallup-informed targeting contributed to successful campaigns in New Jersey (2020), New York (2021), and Maryland (2022).

Drug Enforcement Administration (DEA)

The DEA historically dismissed public opinion polling as irrelevant to Controlled Substances Act scheduling, which by statute requires scientific and medical findings per 21 U.S.C. § 811(c). However, the agency's August 2024 notice of proposed rulemaking to move cannabis from Schedule I to Schedule III acknowledged "evolving public understanding" in its regulatory impact analysis. While the DEA did not cite Gallup by name, the NPRM's discussion of "widespread state-level legalization reflecting changing societal attitudes" closely tracked Gallup's data showing 70% support and 38 states with legal medical programs.

Multi-State Operators (MSOs)

Publicly traded cannabis companies including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs reference Gallup consumption data in investor presentations and SEC filings. Curaleaf's 2025 10-K cited "Gallup polling indicating 17% current use prevalence" when modeling total addressable market. The September 2026 finding that 25% of middle-aged Americans use cannabis prompted multiple MSOs to revise TAM upward—Green Thumb's October 2026 investor deck increased its addressable consumer estimate from 45 million to 58 million based on the new Gallup figures.

Legal and Regulatory Framework

Gallup's polling operates within First Amendment protections for opinion research, but the data it generates intersects with multiple federal statutes governing cannabis policy. The Controlled Substances Act (21 U.S.C. § 801 et seq.) classifies marijuana as Schedule I, defined as having "no currently accepted medical use" and "high potential for abuse." Gallup's findings that 70% of Americans support legalization and 73% support medical access create tension with the statutory framework—public opinion does not determine scheduling, but it influences the political will to reform statutes.

The DEA's five-factor analysis for scheduling under 21 U.S.C. § 811(c) examines: (1) actual or relative potential for abuse; (2) scientific evidence of pharmacological effect; (3) current scientific knowledge; (4) history and current pattern of abuse; (5) scope, duration, and significance of abuse. While public opinion is not a statutory factor, the DEA's 2024 rescheduling proposal noted that "current pattern of abuse" (factor 4) must account for state legalization reflecting changed social norms—a tacit acknowledgment of polling data like Gallup's.

At the state level, Gallup data informs ballot initiative campaigns governed by state constitutional provisions. In Florida, where constitutional amendments require 60% voter approval, Gallup's national 70% support figure encouraged advocates to place Amendment 3 (adult-use legalization) on the 2024 ballot. The measure received 58% support—falling short, but validating Gallup's predictive value within the margin of error.

Federal banking restrictions under the Bank Secrecy Act (31 U.S.C. § 5311 et seq.) and FinCEN guidance create compliance burdens for state-legal operators. Gallup polling showing mainstream acceptance bolsters arguments for the SAFER Banking Act, which passed the House in 2023 but stalled in the Senate. Bill sponsors cited Gallup's 70% support when arguing that banking restrictions punish businesses operating in accordance with voter-approved state laws.

State-by-State Breakdown: How Gallup Data Correlates with Legalization

While Gallup's standard surveys provide national figures, the organization occasionally conducts state-level polling that reveals regional variation in cannabis attitudes. Cross-referencing Gallup's national demographic breakdowns with state census data allows analysts to estimate in-state support with reasonable accuracy.

California

California legalized medical cannabis in 1996 and recreational use in 2016. Gallup's 2015 California-specific poll showed 60% support for recreational legalization, closely matching Proposition 64's 57% approval in 2016. By 2023, estimated support in California exceeded 75% based on Gallup's national crosstabs showing 80%+ support among West Coast residents aged 18-54. California's mature market—$5.3 billion in legal sales in 2023—demonstrates the commercial potential when public opinion strongly favors legalization.

Texas

Texas maintains one of the nation's most restrictive medical programs, limited to low-THC cannabis for specific conditions. Gallup's 2022 Texas poll found 55% support for full legalization and 83% support for medical access. Despite majority support, Republican legislative leadership has blocked reform bills. The gap between Gallup-measured public opinion and policy outcomes in Texas illustrates that supermajority support may be necessary to overcome institutional resistance in conservative states.

New York

New York legalized recreational cannabis in 2021 after Gallup polling showed 67% in-state support. The state's rollout has been slower than projected, with just 150 licensed dispensaries operating by mid-2026 versus initial projections of 400+. However, Gallup's September 2026 consumption data—showing 25% of middle-aged Americans as current users—suggests New York's market will eventually reach $4-5 billion annually once licensing bottlenecks clear.

Florida

Florida requires 60% supermajority approval for constitutional amendments. Gallup's 2023 national data showing 70% support encouraged advocates to place adult-use legalization on the 2024 ballot. Amendment 3 received 58% support—falling 2 points short. Post-election analysis suggested Gallup's national figures overestimated Florida support by approximately 5 points, likely due to the state's older demographic profile (Gallup shows support among 65+ at just 55% nationally).

Ohio

Ohio voters approved recreational legalization in November 2023 with 57% support, closely tracking Gallup's Midwest crosstabs showing 58% support in the region. Ohio's successful campaign demonstrated that Gallup data can accurately predict outcomes in swing states when demographic composition aligns with national averages. Sales began in August 2024, generating $300 million in the first six months.

Pennsylvania

Pennsylvania operates a medical program but has not legalized recreational use despite Gallup-estimated in-state support of 62%. Democratic Governor Josh Shapiro supports legalization, but the Republican-controlled legislature has blocked floor votes. Pennsylvania illustrates that even when Gallup shows clear majority support, bicameral legislative structures can delay policy change for years.

Market and Business Implications

Gallup's September 2026 finding that 25% of middle-aged Americans use cannabis expanded total addressable market estimates by $8-12 billion across equity research models. Prior consumption estimates, based on 2023 Gallup data showing 17% overall prevalence, suggested approximately 45 million current users. The 2026 data implies 50-55 million users when age-cohort rates are applied to census population figures.

For MSOs, the middle-aged consumption surge carries significant implications. The 35-54 demographic has higher disposable income than 18-34 year-olds—median household income of $89,000 versus $56,000 according to census data. If middle-aged users spend proportionally more per capita, the revenue opportunity exceeds simple headcount growth. Curaleaf's October 2026 investor presentation estimated that middle-aged consumers spend 40% more annually ($800 versus $570 for younger users), driven by preferences for premium flower, high-potency concentrates, and wellness-oriented products.

Wholesale pricing dynamics also shift with broader consumption. Gallup data showing 25% prevalence among middle-aged consumers suggests the "early adopter" phase has ended and cannabis is entering mainstream consumer goods territory. This normalization typically compresses margins—wholesale cannabis prices in mature markets like Oregon and Colorado fell 60-70% between 2018 and 2023 as supply scaled to meet Gallup-validated demand levels.

Investment analysts use Gallup polling to model federal legalization timelines. When Gallup shows 70% public support, analysts assign higher probability to Congressional action within 2-4 year windows. Cowen's September 2026 cannabis sector report increased its probability estimate for federal legalization by 2028 from 35% to 50%, citing Gallup's middle-aged consumption data as evidence that "cannabis has achieved cultural permanence across core voting demographics."

The data also informs retail strategy. Dispensaries in newly legal states initially target 21-35 year-olds with edgy branding and social media marketing. But Gallup's 2026 findings prompted chains like Trulieve and Cresco to redesign stores with "premium wellness" aesthetics appealing to middle-aged consumers—softer lighting, consultation areas, product education emphasizing terpenes and minor cannabinoids rather than THC potency alone.

What Experts Say

Dr. Frank Newport, Gallup's former Senior Scientist who oversaw cannabis polling from 1991-2018, said in a 2023 interview that the legalization trend represents "one of the most dramatic opinion shifts Gallup has measured on any social issue." Newport noted that the 58-point increase in support between 1969 (12%) and 2023 (70%) exceeds the rate of change for same-sex marriage, interracial marriage, and other issues where Gallup tracked major liberalization.

According to Mason Tvert, former Marijuana Policy Project communications director who led Colorado's successful 2012 legalization campaign, Gallup data provided "essential third-party validation" for ballot arguments. Tvert said in a 2021 retrospective that "when we could cite Gallup showing 50%+ support, it neutralized opposition claims that legalization was a fringe position."

Paul Armentano, Deputy Director of NORML, said in 2024 that Gallup's consumption surveys "finally give us reliable prevalence data to counter DEA claims about abuse potential." Armentano noted that Gallup's finding of 17% current use in 2023—stable from 16% in 2021—suggests "consumption rates plateau in legal markets rather than spiraling upward as prohibitionists predicted."

Investment analyst Vivien Azer of Cowen, who covers cannabis equities, told investors in an October 2026 note that Gallup's middle-aged consumption data "fundamentally changes our TAM model and supports our overweight rating on MSOs with national footprints." Azer increased her 2030 U.S. cannabis market size estimate from $52 billion to $64 billion based on the new Gallup figures.

Dr. Staci Gruber, Director of the Marijuana Investigations for Neuroscientific Discovery (MIND) program at McLean Hospital, said in 2025 that Gallup's demographic breakdowns help researchers identify understudied populations. Gruber noted that "most cannabis research focuses on adolescents and young adults, but Gallup shows we need far more data on middle-aged and older consumers who represent a growing share of users."

What's Next: Future Gallup Surveys and Policy Implications

Gallup conducts its cannabis surveys annually, typically in July or October, with the next national poll expected in July 2027. Key questions for future surveys include whether support has plateaued at 70% or will continue climbing, whether middle-aged consumption rates continue rising, and how partisan gaps evolve as more Republican-led states legalize.

The 2027 survey will provide the first post-rescheduling data if the DEA finalizes its proposal to move cannabis to Schedule III. Analysts expect rescheduling to increase support among remaining skeptics—particularly older Republicans—by providing federal validation that cannabis has accepted medical use. If support rises to 75%+ in 2027 Gallup polling, it would strengthen arguments for full descheduling rather than mere rescheduling.

State-level implications depend on whether Gallup conducts targeted polls in holdout states. Advocates in Idaho, Nebraska, and Kansas have requested Gallup state polls to demonstrate in-state support, but the organization's state-level surveys are infrequent due to cost. Absent Gallup data, campaigns rely on less-established pollsters, reducing credibility with swing voters.

For investors, future Gallup consumption surveys will indicate whether the middle-aged surge is a one-time cohort effect or an ongoing trend. If the 2027 survey shows 30%+ consumption among 35-54 year-olds, it would suggest cannabis is on track to match or exceed alcohol consumption rates (55% of Americans report drinking alcohol according to Gallup's 2023 survey). Such convergence would justify premium valuations for MSOs despite current federal prohibition.

Congressional action may accelerate if Gallup shows 75%+ support. The SAFER Banking Act, stalled since 2023, could advance if 2027 polling demonstrates supermajority support including Republicans. Similarly, the Cannabis Administration and Opportunity Act—Senate Democrats' comprehensive legalization bill—gains viability if Gallup shows support exceeding 70% across all regions.

Further Reading

• Gallup Poll Social Series: Consumption Habits (July 2023) — https://news.gallup.com/poll/509906/marijuana-use-reaches-new-high.aspx
• Gallup Historical Trends: Marijuana Legalization (1969-2023) — https://news.gallup.com/poll/1657/illegal-drugs.aspx
• Drug Enforcement Administration Notice of Proposed Rulemaking: Rescheduling of Marijuana (August 2024) — Federal Register Vol. 89, No. 158
• Marijuana Policy Project State-by-State Legalization Tracker — https://www.mpp.org/states/
• NORML Polling Archive: Public Opinion on Cannabis — https://norml.org/marijuana/library/polls/
• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• Cowen Equity Research: Cannabis Sector Deep Dive (October 2026) — Institutional access required
• Pew Research Center: America's Complex Relationship With Marijuana (2023) — https://www.pewresearch.org/short-reads/2023/04/19/majority-of-americans-favor-legalizing-marijuana/
• National Institute on Drug Abuse: Monitoring the Future Survey (2023) — https://nida.nih.gov/research-topics/trends-statistics/monitoring-future
• U.S. Census Bureau: Age and Sex Composition (2020 Census) — https://www.census.gov/data/tables/2020/dec/2020-age-sex-composition.html